Ken Fisher
IGC icon

Ken Fisher’s IGC Pharma IGC Stock Holding History

Ken Fisher’s Portfolio IGC Stock Details IGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.8K Hold
43,400
– – ﹤0.01% 1035
2026
Q1 		$11.4K Hold
43,400
– – ﹤0.01% 1013
2025
Q4 		$12.2K Hold
43,400
– – ﹤0.01% 1014
2025
Q3 		$18.1K Buy
+43,400
New +$16.5K ﹤0.01% 1011

Other funds holding IGC

LC
Lawood & Co Williamsport, Pennsylvania $148M AUM
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
WAP
Wealthcare Advisory Partners West Chester, Pennsylvania $5.27B AUM 22.23% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
DFA
DHJJ Financial Advisors Naperville, Illinois $347M AUM 22.07% 1-Year Est. Return
NF
Napier Financial Braintree, Massachusetts $480M AUM
TCM
Triumph Capital Management Denver, Colorado $552M AUM 20.75% 1-Year Est. Return

Ken Fisher's IGC Position: Q2 2026 in Review

Ken Fisher held its IGC Pharma (IGC) position steady in Q2 2026 at 43,400 shares worth $11.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1035.

Ken Fisher first reported a position in IGC in Q3 2025 and has held it in 4 quarters since. The position peaked at $18.1K in Q3 2025. 10 funds tracked by Wall St. Rank hold IGC as of Q2 2026.

  • Ken Fisher held 43,400 shares of IGC Pharma worth $11.8K as of Q2 2026.
  • Ken Fisher left its IGC Pharma share count unchanged in Q2 2026.
  • IGC Pharma made up ﹤0.01% of Ken Fisher's portfolio in Q2 2026, its #1035 holding.
  • Ken Fisher first reported a position in IGC Pharma in Q3 2025 and has held it in 4 quarters since.
  • Ken Fisher's IGC Pharma position peaked at $18.1K in Q3 2025.
  • 10 funds tracked by Wall St. Rank held IGC Pharma as of Q2 2026.

Based on Fisher Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.